Skip to main content

Table 3 Adverse treatments events

From: Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis

Adverse events Number (proportion%) Grade 1–2, n (proportion%) Grade 3, n (proportion%) Grade 4, n (proportion%)
Abdominal pain 26 (48.1) 26 (48.1) 0 (0) 0 (0)
Fever 23 (42.6) 23 (42.6) 0 (0) 0 (0)
Vomiting 7 (13.0) 7 (13.0) 0 (0) 0 (0)
Ascites 6 (11.1) 6 (11.1) 0 (0) 0 (0)
Pleural effusion 5 (9.3) 5 (9.3) 0 (0) 0 (0)
TBILa increase 28 (81.5) 28 (51.9) 16 (29.6) 0 (0)
ALTb increase 15 (27.8) 10 (18.5) 5 (9.3) 0 (0)
Hypoalbuminemia 43 (79.6) 43 (79.6) 0 (0) 0 (0)
Inguinal hematoma 0 (0) 0 (0) 0 (0) 0 (0)
Gastrointestinal bleeding 0 (0) 0 (0) 0 (0) 0 (0)
Pulmonary embolism 0 (0) 0 (0) 0 (0) 0 (0)
Primary peritonitis 2 (3.7) 0 (0) 2 (3.7) 0 (0)
  1. aTBIL total bilirubin
  2. bALT alanine aminotransferase